Which treatment option is available for someone with an ALK mutation?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Prepare for the CMID Test. Study with flashcards and multiple choice questions, each question contains hints and explanations. Get ready for your exam with confidence!

Multiple Choice

Which treatment option is available for someone with an ALK mutation?

Explanation:
ALK rearrangements drive growth in a subset of non-small cell lung cancers. Crizotinib is an ALK inhibitor that directly blocks the abnormal ALK signaling, slowing or stopping tumor growth in ALK-positive tumors. The other drugs target different molecular drivers: Tamoxifen blocks estrogen receptor signaling in ER-positive breast cancer; Gefitinib inhibits EGFR signaling in EGFR-mutant lung cancers; Herceptin (trastuzumab) targets HER2 overexpression in HER2-positive breast or gastric cancers. Because crizotinib specifically inhibits ALK, it is the treatment option that fits an ALK mutation.

ALK rearrangements drive growth in a subset of non-small cell lung cancers. Crizotinib is an ALK inhibitor that directly blocks the abnormal ALK signaling, slowing or stopping tumor growth in ALK-positive tumors. The other drugs target different molecular drivers: Tamoxifen blocks estrogen receptor signaling in ER-positive breast cancer; Gefitinib inhibits EGFR signaling in EGFR-mutant lung cancers; Herceptin (trastuzumab) targets HER2 overexpression in HER2-positive breast or gastric cancers. Because crizotinib specifically inhibits ALK, it is the treatment option that fits an ALK mutation.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy